Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E37.77 EPS (ttm)8.04 Insider Own0.10% Shs Outstand237.20M Perf Week-2.67%
Market Cap72.03B Forward P/E21.00 EPS next Y14.46 Insider Trans19.08% Shs Float236.96M Perf Month-4.98%
Income1.92B PEG1.99 EPS next Q2.82 Inst Own92.10% Short Float1.33% Perf Quarter-0.83%
Sales7.65B P/S9.42 EPS this Y35.60% Inst Trans-0.10% Short Ratio2.66 Perf Half Y-2.20%
Book/sh38.59 P/B7.87 EPS next Y25.60% ROA16.60% Target Price351.12 Perf Year31.08%
Cash/sh5.31 P/C57.16 EPS next 5Y19.00% ROE22.70% 52W Range203.55 - 358.89 Perf YTD8.62%
Dividend- P/FCF- EPS past 5Y24.10% ROI20.70% 52W High-5.84% Beta1.23
Dividend %- Quick Ratio1.80 Sales past 5Y11.10% Gross Margin86.90% 52W Low66.02% ATR7.22
Employees6850 Current Ratio2.20 Sales Q/Q50.50% Oper. Margin34.60% RSI (14)66.03 Volatility2.51% 2.38%
OptionableYes Debt/Eq0.07 EPS Q/Q12.80% Profit Margin25.00% Rel Volume4.15 Prev Close303.67
ShortableYes LT Debt/Eq0.06 EarningsJul 23 BMO Payout0.00% Avg Volume1.19M Price337.93
Recom2.10 SMA206.98% SMA508.67% SMA20014.77% Volume3,264,780 Change11.28%
09-Jul-14Reiterated RBC Capital Mkts Outperform $325 → $375
19-Mar-14Reiterated Stifel Buy $360 → $376
07-Mar-14Reiterated Barclays Overweight $325 → $352
03-Mar-14Reiterated Stifel Buy $330 → $360
30-Jan-14Reiterated UBS Neutral $300 → $310
30-Jan-14Reiterated Brean Capital Buy $293 → $377
30-Jan-14Reiterated Argus Buy $310 → $360
28-Jan-14Reiterated Deutsche Bank Buy $340 → $415
27-Jan-14Reiterated Canaccord Genuity Buy $291 → $355
16-Jan-14Reiterated Stifel Buy $296 → $321
10-Jan-14Reiterated Barclays Overweight $285 → $325
20-Dec-13Reiterated RBC Capital Mkts Outperform $275 → $325
12-Dec-13Reiterated Argus Buy $280 → $310
30-Oct-13Initiated FBR Capital Mkt Perform $259
29-Oct-13Reiterated Barclays Overweight $240 → $262
17-Jul-13Reiterated Barclays Overweight $220 → $240
09-May-13Reiterated MKM Partners Neutral $208 → $215
29-Apr-13Reiterated Argus Buy $195 → $250
26-Apr-13Reiterated Canaccord Genuity Buy $206 → $231
26-Apr-13Reiterated Barclays Overweight $210 → $220
23-Jul-14 01:29PM  S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade at Investor's Business Daily +11.28%
01:16PM  Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 Zacks
12:40PM  [video] Biotech blowout: Biogen & Gilead at CNBC
12:37PM  Stock market live blog: S&P 500 rises to intraday record; Apple jumps nearly 3% at MarketWatch
12:20PM  Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines Zacks
12:05PM  Stock market live blog: S&P 500 rises to intraday record; Apple jumps nearly 3% at MarketWatch
11:56AM  Biogen Trounces Q2 Estimates As Tecfidera Outperforms at Investor's Business Daily
11:52AM  U.S. stocks rise; S&P 500 sets intraday record at MarketWatch
11:45AM  [video] Biogen CEO: Want to stop inversions? Reform tax code at CNBC
11:41AM  PLEGRIDY (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis Business Wire
11:19AM  Today's Market: Biotech Names Rallying Today at Seeking Alpha
11:07AM  Stock market live blog: S&P 500 rises to intraday record; Apple jumps nearly 3% at MarketWatch
11:02AM  Stock market live blog: S&P 500 rises to intraday record; Apple jumps nearly 3% at MarketWatch
10:54AM  Biogen Idec: Biggest Beat in 10 Years, Largest Leap in Eight Months at Barrons.com
10:49AM  Biogen earnings: A lesson in how to boost an already pricey stock at MarketWatch
10:44AM  Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck Up at Investor's Business Daily
10:43AM  Biogen Idec Stock Spikes Following Second Quarter Earnings Beat at TheStreet
10:25AM  Biogen price target raised to $420 from $370 at Piper Jaffray at theflyonthewall.com
10:25AM  Stock market live blog: S&P 500 turns flat after intraday record; Boeing weighs on Dow at MarketWatch
09:50AM  Biogen says strategic bias still tuck-in acquisitions at theflyonthewall.com
09:48AM  As S&P nears 2,000, traders say keep an eye on this at CNBC
09:25AM  Biogen sees Japan as an attractive growth opportunity for company at theflyonthewall.com
09:07AM  Biogen Idec (BIIB) Stock Spikes Following Second Quarter Earnings Beat at TheStreet
09:05AM  Biogen says received letter from EU saying PLEGRIDY has been approved theflyonthewall.com
09:00AM  Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising at Investor's Business Daily
09:00AM  Biogen Idec Inc Earnings Call scheduled for 9:00 am ET today CCBN
08:48AM  Wednesdays Top Health Care Stories: Puma, Biogen, and Intuitive Surgical at Motley Fool
08:35AM  BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
08:22AM  Biogen, Microsoft gain; Whirlpool, Juniper sink at MarketWatch
07:32AM  [$$] Biogen Idec's Profit Surges at The Wall Street Journal
07:07AM  Q2 2014 Biogen Idec Inc. Earnings Release - Before Market Open CCBN
07:04AM  Biogen revenue trounces forecast as MS drug sales surge Reuters
07:03AM  Biogen Beats Quarterly Analyst Estimates with New Drug Sales at Bloomberg
06:45AM  Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year Business Wire
22-Jul-14 05:02PM  Could This 1 Lawsuit Destroy Biogen Idec Stock? at Motley Fool
02:44PM  3 Stocks Reiterated As A Buy: CAT, BIIB, AMGN at TheStreet
12:50PM  Will Biogen Idec Inc. (BIIB) Surprise this Earnings Season? Zacks
12:42PM  Alexion, 3 Other Top Biotechs Reporting Earnings at Investor's Business Daily
06:40AM  Is a Surprise Coming for Biogen Idec (BIIB) This Earnings Season? Zacks
21-Jul-14 06:51PM  Oil Dominates; Keurig, Constellation Near Buy Points at Investor's Business Daily
04:09PM  Biogen Shares Rebound As Street Has A Change Of Heart at Investor's Business Daily
01:33PM  Big Week of Earnings for Big Biotech ETF ETF Trends
10:25AM  Evaluating Biogen Idec After The Sell-Off at Seeking Alpha
08:06AM  Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher Zacks
07:03AM  bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% Zacks
20-Jul-14 09:11AM  Top Biotech Earnings Previews for the Week Ahead at 24/7 Wall St.
18-Jul-14 06:30PM  Politics fade as earnings take over at CNBC
03:40PM  Biotech Enters Reporting Season With Large Caps Central To Sector Performance Benzinga
08:24AM  An Open Letter To Janet Yellen: Is There A Biotech Bubble? at Forbes
17-Jul-14 12:29PM  Baxter Q2 Earnings Beat Estimates, But Guidance Soft at Investor's Business Daily
09:42AM  Yellen Fire In The Biotech Theater at Forbes
06:38AM  Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% Zacks
16-Jul-14 07:46PM  Why Express Scripts Inc., Monster Beverage Corporation, and Biogen Idec Inc. Are Today's 3 Worst Stocks at Motley Fool
03:30PM  Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Zacks
08:00AM  Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS) Business Wire
15-Jul-14 02:10PM  CVS Caremark to Expand with Navarro Discount Pharmacy Buyout Zacks
12:59PM  3 Stocks Reiterated As A Buy: WMT, CMCSA, BIIB at TheStreet
06:38AM  Exelixis (EXEL) Soars: Stock Adds 23% in Session Zacks
14-Jul-14 06:56PM  IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market at Investor's Business Daily
05:45PM  Sunesis' Pediatric Plan Accepted in the EU Zacks
03:45PM  Will Johnson & Johnson (JNJ) Beat this Earnings Season? Zacks
01:03PM  ABBV, BIIB And CELG, Pushing Drugs Industry Downward at TheStreet
11-Jul-14 04:40PM  Stocks Close Higher As Biotech, Internet Stocks Gain at Investor's Business Daily
03:06PM  Gilead Sciences: The Senate Just Wrote Me a Letter at Barrons.com
02:00PM  Oncolytics Up on Patient Enrolment Completion Zacks
01:06PM  The fight against Alzheimer's CNBC
01:06PM  [video] The fight against Alzheimer's at CNBC
06:52AM  [video] Big pharma's big battle with Alzheimer's at CNBC
06:46AM  Should You Get Rid of Kamada (KMDA) Now? Zacks
10-Jul-14 05:30PM  Regado's REGULATE-PCI Study Under Clinical Hold Zacks
05:10PM  Myriad Genetics Poised on Strong Fundamentals Zacks
10:07AM  Regeneron Picked a Heck of a Day to Announce Good News at Barrons.com
06:00AM  Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM at TheStreet
09-Jul-14 06:29PM  Cramer: 4 strong stocks for months to come at CNBC
06:25PM  [video] Four horseman of biotech have a lot of upside: Cramer at CNBC
07:51AM  China Biologic Products, Inc. (CBPO) Jumps: Stock Surges 10.8% Zacks
08-Jul-14 05:46PM  [video] Biotech buys right now at CNBC
05:21PM  Top Large-Cap Funds Way Above Group's Average at Investor's Business Daily
03:45PM  BioDelivery Jumps after Pain Drug Performs Well in Study Zacks
02:42PM  Alexion Pharma Looks To Life Beyond Its Blockbuster at Investor's Business Daily
10:03AM  Gilead Sciences: How Big a Beat? at Barrons.com
07:04AM  BioDelivery Sciences International (BDSI) Rises: Stock Jumps 8.9% Zacks
07-Jul-14 05:10PM  UCB, Dermira Sign Cimzia Dermatology Deal Zacks
12:31PM  [video] Why GoPro Stock Is a Hand Grenade at Bloomberg
03-Jul-14 04:10PM  Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up Zacks
01:30PM  Genomic Grows on Breast Cancer Test, Margin Pressure Continues Zacks
12:38PM  Gilead Sciences: Time for an Earnings Beat? at Barrons.com
12:26PM  Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector Benzinga
02-Jul-14 06:15PM  Vertex Pharmaceuticals Up on Kalydeco sNDA Submission Zacks
10:30AM  Regeneron Shares Jump as Sanofi Increases Stake Zacks
06:50AM  Strength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46% Zacks
06:06AM  Cramer's Mad Money - The Mother Of All Speculative Stocks (7/1/14) at Seeking Alpha
01-Jul-14 06:08PM  Cramer: Six buyable themes in second half at CNBC
06:08PM  Cramer: 6 buyable themes in second half at CNBC
06:01PM  Top Large-Cap Growth Funds Defy The Odds at Investor's Business Daily
05:08PM  Is this Biogen's Biggest Risk? at Motley Fool
03:25PM  Gilead Sciences Inc.'s Upcoming Catalyst(s) at Motley Fool
11:29AM  Biotech: Buy the Trial, Sell the Approval? at Barrons.com
30-Jun-14 05:00PM  Biogen Hemophilia Drugs Launch Into The Unknown at Investor's Business Daily
04:01PM  Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014 Business Wire
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 03 05:29 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15909,730Feb 03 05:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,586010,097Feb 03 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,159010,044Feb 03 05:15 PM
Rowinsky Eric KDirectorJan 21Sale310.092,020626,38210,440Jan 22 04:49 PM
YOUNG WILLIAMDirectorJan 08Sale285.1115,0004,276,59018,509Jan 09 04:24 PM
PANGIA ROBERT WDirectorJan 06Option Exercise47.556,250297,18820,253Jan 07 12:22 PM
PANGIA ROBERT WDirectorJan 06Sale278.036,2501,737,68814,003Jan 07 12:22 PM
SHERWIN STEPHEN ADirectorJan 02Option Exercise59.825,500329,0109,460Jan 06 11:19 AM
SHERWIN STEPHEN ADirectorJan 02Sale279.285,5001,536,0593,960Jan 06 11:19 AM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale285.90439125,51013,667Dec 05 02:53 PM
SCHENK LYNNDirectorDec 02Sale291.711,000291,7104,100Dec 02 03:28 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Option Exercise49.954,000199,80012,710Nov 25 02:11 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Sale288.004,0001,152,0008,710Nov 25 02:11 PM
SCHENK LYNNDirectorNov 01Sale245.001,000245,0005,100Nov 05 12:18 PM
SCANGOS GEORGE AChief Executive OfficerNov 01Sale245.572,239549,83139,044Nov 05 12:13 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerOct 22Option Exercise60.5615,030910,21729,530Oct 23 05:03 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerOct 22Sale250.1115,0303,759,12314,500Oct 23 05:03 PM
SCHENK LYNNDirectorOct 01Sale242.851,000242,8506,100Oct 02 05:09 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale242.852,239543,74141,283Oct 02 04:35 PM
DiPietro KennethEVP Human ResourcesSep 30Sale242.001,440348,4800Oct 02 01:36 PM
Clancy Paul JExecutive VP and CFOSep 18Option Exercise49.6526,7851,329,87533,872Sep 19 02:14 PM
Clancy Paul JExecutive VP and CFOSep 18Sale245.0026,7856,562,3257,087Sep 19 02:14 PM
Pawlicki RaymondSVP, Chief Information OfficerSep 16Option Exercise49.594,000198,36012,710Sep 18 04:26 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerSep 16Option Exercise49.659,820487,56324,320Sep 18 04:28 PM
Clancy Paul JExecutive VP and CFOSep 16Option Exercise56.1199,0305,556,89551,027Sep 18 04:34 PM
Clancy Paul JExecutive VP and CFOSep 16Sale238.2799,03023,596,3117,087Sep 18 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerSep 16Sale240.109,8202,357,82114,500Sep 18 04:28 PM
Pawlicki RaymondSVP, Chief Information OfficerSep 16Sale238.034,000952,1208,710Sep 18 04:26 PM
SCHENK LYNNDirectorSep 11Sale235.25900211,7263,325Sep 13 02:33 PM
SCANGOS GEORGE AChief Executive OfficerSep 03Sale214.402,239480,04243,522Sep 04 04:52 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentAug 26Sale211.354,368923,1684,571Aug 28 12:30 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale218.822,239489,93845,761Aug 02 10:55 AM